Congressionally Directed Medical Research Programs -- Combat Readiness – Medical Research Program -- Rapid Development and Translational Research Award

Funding Agency:
Department of Defense

Treating and returning military personnel to duty, which maintains Force strength and lethality, has always been a primary mission of the Services. In the wars in Iraq and Afghanistan, the U.S. military achieved the highest rate of survival from battlefield injuries in history. The woundedto-killed ratio more than doubled, from 4:1 during last century’s world wars, to 10:1 today.1 Substantial credit for this achievement is due to a 2009 Congressional mandate that stated wounded Warfighters should be provided with life-saving care within 60 minutes of injury, a timespan that is referred to as the “golden hour.” At the time, the battlefield had numerous forward surgical teams, combat support hospitals, and medevac assets from all Services. The available infrastructure mitigated the need for prolonged field care and enabled transportation of casualties to a damage control capability in traditional Role of Care 2 or Role of Care 3 environments where “golden hour” medical assets and interventions were available.

The time-specific window of the “golden hour” does not accurately reflect current trauma care considerations and may not be feasible for Warfighters in battlefield environments, thus, there is a need to enable readiness to bring effective and efficient capabilities for acute, life-saving care in non-hospital settings closer to the point of injury and provide prolonged field care (greater than 72 hours) where necessary.

The CRRP seeks to enhance medical capabilities and Force readiness at the point of greatest need in order to save the most lives in trauma care scenarios, which may be complicated by combat operations, limited resources, austere conditions, and/or mass casualty events. The intent of the FY20 CRRP RDTRA is to support research that will accelerate the movement of promising ideas into clinical applications, including healthcare products, technologies, and/or practice guidelines.

Research under this award mechanism should represent a rapid advancement or innovative “leap ahead” and have the potential for broadly applicable, crosscutting advances benefiting military health and medicine as well as the general public. Applicants may leverage existing resources in translational research to address high-impact research ideas or unmet needs to enable the delivery of life-saving care to the Warfighter during prolonged and en route care in austere and combat environments. Research of interest may include knowledge products, “knowledge resulting from research with the potential to improve individual or public health,”2 and solutions that can accelerate the introduction of militaryrelevant health products or technologies into clinical and/or operational use.


• Required Pre-Application Deadline:  September 10, 2020

• Application Submission Deadline:  December 3, 2020

Agency Website

Areas of Interest

The Focus Areas were established from research priorities described in the Congressional Committee Report for the CRRP in FY20. These Focus Areas broadly describe current priorities to improve readiness for delivering frontline care in combat situations and for delivering medical damage control capability, assets, and life-saving interventions during prolonged and en route care in austere and combat environments, including the acute and early management of combatrelated trauma at the point of injury. Proposals/applications submitted to the FY20 CRRP RDTRA must address at least one of the FY20 CRRP RDTRA Focus Areas listed below. Selection of the appropriate FY20 CRRP RDTRA Focus Area is the responsibility of the applicant.

Funding should be used for the research and development of one of the following Focus Areas:

  • Multiple-use scalable wound-care solutions that can address prevention of bleeding and infection, delivery of therapeutics, and promotion of healing spanning the operational medical care continuum or roles of care (e.g., acute through chronic care).
  • Repair and/or restoration of combat-related genitourinary organ and tissue damage.
  • Solutions for assessment of mild traumatic brain injury (mTBI) in deployed and far-forward settings, to include portable devices.
  • Freeze-dried plasma and platelets for hemorrhage control and resuscitation.
  • Solutions to enhance Warfighter readiness in battlefield and austere environments including the prevention and treatment of the following: ○ Gastrointestinal illness such as Enterotoxigenic Escherichia coli diarrheal disease and inflammatory bowel disease ○ Sleep disorders ○ Myalgic encephalomyelitis/chronic fatigue syndrome ○ Infectious diseases
  • Enhanced delivery and utilization of telemedicine platforms

Eligibility Requirements

Independent investigators at all academic levels (or equivalent) are eligible to be named by the organization as the PI in the proposal/application. There are no limitations on the number of proposals/applications for which an investigator may be named as a PI. An eligible PI, regardless of ethnicity, nationality, or citizenship status, must be employed by, or affiliated with, an eligible organization.



Amount Description

The anticipated total costs budgeted for the entire period of performance for an FY20 CRRP RDTRA will not exceed $2M. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.

Funding Type



Junior Faculty


Medical - Basic Science
Medical - Clinical Science
Medical - Translational

External Deadline

September 10, 2020